STELLA PHARMA CORPORATION

As of March 31, 2026, STELLA PHARMA CORPORATION carries a market capitalization of 25.82B, placing it among publicly traded companies globally. Its enterprise value stands at 23.75B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

STELLA PHARMA CORPORATION's next confirmed earnings release is scheduled for November 13, 2026.

As of March 31, 2026, STELLA PHARMA CORPORATION has 34.02M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, STELLA PHARMA CORPORATION maintains a current ratio of 16.75, meaning it holds 16.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, STELLA PHARMA CORPORATION's stock has gained approximately 21.13% over the past 52 weeks. The 50-day moving average sits at 387.06, while the 200-day moving average is 405.39.

As of March 31, 2026, STELLA PHARMA CORPORATION holds 2.82B in cash and equivalents against 747.14M in total debt, resulting in a net debt position of -2.08B. Total book value stands at 2.43B, with working capital of 4.09B providing operational flexibility.